ReviewEuropean journal of neurology2024
Guillain-Barré syndrome: a comprehensive review.
Review in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Time- and threshold-dependent cerebrospinal fluid protein elevation and albuminocytologic dissociation in Guillain-Barré syndrome: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review.Clinical pharmacokinetics · 2026Pooled it
- Dengue virus infection and Guillain-Barré syndrome: a systematic review of clinical characteristics, outcomes, and predictors of severity.BMC infectious diseases · 2025Pooled it
- Neuro-immune interactions in tumors, immune-related disorders, and infections.Signal transduction and targeted therapy · 2026Review
- Pediatric Guillain-Barré Syndrome Post Organ Transplant: Acute and Chronic Complication Requiring High Index of Suspicion.Pediatric transplantation · 2026Article
- In Cases of Immunoglobulin Failure in Acute Motor Axonal Neuropathy and Miller Fisher Syndrome, Plasma Exchange Should be Performed Early.Internal medicine (Tokyo, Japan) · 2026Article
- Reply to the Editor.Internal medicine (Tokyo, Japan) · 2026Article
- Autonomic Dysfunction After Guillain-Barré Syndrome: Evidence from Comprehensive Autonomic Testing.Journal of clinical medicine · 2026Article
- Response to Comments on: Guillain-Barre Syndrome With Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation.The Kaohsiung journal of medical sciences · 2026Article
- Diagnostic and therapeutic potential of resolvin D1 in Guillain-Barré syndrome.Journal of advanced research · 2026Article
- Acute Management of Guillain-Barré Syndrome: A Narrative Review.Archives of internal medicine research · 2026Article
- Article
- From Kidneys to Nerves: A Rare Case of a Urinary Tract Infection Triggering Guillain-Barré Syndrome.Cureus · 2026Article
- Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in US Medicare Adults Age 65 Years or Older.Drug safety · 2026Article
- Decoding the association between microorganisms and autoimmunity: a multifaceted review of evidence on specific pathogens that trigger autoimmune diseases.Clinical and experimental medicine · 2026Review
- Aerobic exercise is associated with divergent regulation of macrophage migration inhibitory factor and enhanced remyelination in experimental autoimmune neuritis.Bioscience reports · 2026Article
- Article
- Diagnostic challenges and lessons learned of Guillain-Barré syndrome mimicking central nervous system infection - a case report.BMC neurology · 2026Article
- Varicella-zoster virus infection triggering GD3 antibody-positive variant Guillain-Barré syndrome: a case report and literature review.BMC neurology · 2026Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome (GBS) is a potentially devastating yet treatable disorder. A classically postinfectious, immune-mediated, monophasic polyradiculoneuropathy, it is the leading global cause of acquired neuromuscular paralysis. In most cases, the immunopathological process driving nerve injury is ill-defined. Diagnosis of GBS relies on clinical features, supported by laboratory findings and electrophysiology. Although previously divided into primary demyelinating or axonal variants, this dichotomy is increasingly challenged, and is not endorsed by the recent European Academy of Neurology (EAN)/Peripheral Nerve Society (PNS) guidelines. Intravenous immunoglobulin and plasma exchange remain the primary modalities of treatment, regardless of the electrophysiological subtype. Most patients recover, but approximately one-third require mechanical ventilation, and 5% die. Disease activity and treatment response are currently monitored through interval neurological examination and outcome measures, and the potential role of fluid biomarkers is under ongoing scrutiny. Novel potential therapies for GBS are being explored but none have yet modified clinical practice. This review provides a comprehensive update on the pathological and clinical aspects of GBS for clinicians and scientists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.